SCHEMBL5887201

SCHEMBL5887201

COc1ccc(CNC(=O)c2ccc(-n3c(=O)ccc4c(C)nc(N5CCN(C(=O)c6ccco6)CC5)nc43)cc2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.47
ALDH1A1 P00352 6/20 0.47
LMNA P02545 4/20 0.47
GLA P06280 3/20 0.47
GAA P10253 3/20 0.47
MAPT P10636 3/20 0.47
HSD17B10 Q99714 3/20 0.47
NPC1 O15118 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CYP3A4 P08684 2/20 0.47
HPGD P15428 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 2/20 0.47
ADRA1A P35348 2/20 0.47
ADRA1B P35368 2/20 0.47
OPRM1 P35372 2/20 0.47
RAB9A P51151 2/20 0.47
SLC22A2 O15244 1/20 0.47
SLC22A1 O15245 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5886748 0.90 ALDH1A1 (0.43) KDM4EALDH1A1LMNAGLAGAA
SCHEMBL5887006 0.90 ACHE (0.48) ALDH1A1LMNAGAAMAPTNPC1
SCHEMBL5887187 0.89 ALDH1A1 (0.47) KDM4EALDH1A1LMNAGLAGAA
SCHEMBL5886766 0.89 NPC1 (0.45) ALDH1A1LMNAGAAMAPTHSD17B10
SCHEMBL5886825 0.89 NPC1 (0.45) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL5887467 0.88 KDM4E (0.46) KDM4EALDH1A1LMNAGAAMAPT
SCHEMBL5887021 0.88 SMN1; SMN2 (0.45) KDM4EALDH1A1MAPTHSD17B10NPC1
SCHEMBL5887375 0.87 NPC1 (0.44) ALDH1A1LMNAMAPTHSD17B10NPC1
SCHEMBL5886765 0.87 MAPT (0.48) ALDH1A1LMNAMAPTHSD17B10NPC1
SCHEMBL5887045 0.87 SMN1; SMN2 (0.49) ALDH1A1LMNAMAPTHSD17B10NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP KDM4E 840/4885ALDH1A1 1860/4885LMNA 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.